Temporal Changes in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use in Patients with Chronic Kidney Disease and Type 2 Diabetes, 20122023: A US Cohort Study
This creates the perfect environment for glutathione effectiveness
The results of REWIND support consideration of GLP1RA for primary prevention
In 2014, the Food and Drug Administration (FDA) first approved the use of GLP-1s for weight loss, and the results have been nothing short of transformative for many patients
The analyses were conducted on the above cohorts: (1) SGLT2i and (2) GLP-1 RA with each analysis propensity score matched (PSM) for age, sex, BMI, presence of heart failure (ICD-10-CM-I50), hypertension (ICD-10-CM-I10), ischaemic heart disease (IHD) (ICD-10-CM-I2025), chronic kidney disease (CKD) (ICD-10-CM-N18) and HbA 1c value so as to balance the analysis (1:1 matching) being undertaken
& Schoumacher, F